Drug induced steatohepatitis: An uncommon culprit of a common disease

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Rabinowich, Liane ^a   Shibolet, Oren ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; FATTY ACID; GLUCOCORTICOID; METHOTREXATE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; TAMOXIFEN; VALPROIC ACID;

ARTICLE; CELL COUNT; CHEMOTHERAPY; DRUG INDUCED STEATOHEPATITIS; DRUG METABOLISM; FATTY LIVER; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; LIPOGENESIS; LIVER CELL; LIVER TOXICITY; MACROVESICULAR STEATOSIS; MICROVESICULAR STEATOSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); TOXIC HEPATITIS; BIOLOGICAL MODEL; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHEMICALLY INDUCED; METABOLISM; RARE DISEASE;

CHEMICAL AND DRUG INDUCED LIVER INJURY; FATTY LIVER; HUMANS; MODELS, BIOLOGICAL; RARE DISEASES;

EID: 84939184350     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/168905     Document Type: Article

References (140)

1. R. J. Fontana, "Acute liver failure including acetaminophen overdose," Medical Clinics of North America, vol. 92, no. 4, pp. 761-794, 2008.
2. D. Larrey, "Epidemiology and individual susceptibility to adverse drug reactions affecting the liver," Seminars in Liver Disease, vol. 22, no. 2, pp. 145-155, 2002.
3. E. S. Björnsson, O. M. Bergmann, H. K. Björnsson, R. B. Kvaran, and S. Olafsson, "Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of iceland ," Gastroenterology, vol. 144, no. 7, pp. 1419-1425, 2013.
4. M. Lazo, R. Hernaez, M. S. Eberhardt et al. , "Prevalence of nonalcoholic fatty liver disease in the United States: the third national health and nutrition examination survey, 1988-1994," American Journal of Epidemiology, vol. 178, no. 1, pp. 38-45, 2013.
5. G. Bedogni, L. Miglioli, F. Masutti, C. Tiribelli, G. Marchesini, and S. Bellentani, "Prevalence of and risk factors for nonalcoholic fatty liver disease: the dionysos nutrition and liver study," Hepatology, vol. 42, no. 1, pp. 44-52, 2005.
6. J. D. Browning, L. S. Szczepaniak, R. Dobbins et al. , "Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity," Hepatology, vol. 40, no. 6, pp. 1387-1395, 2004.
7. D. L. White, F. Kanwal, and H. B. El-Serag, "Associationbetween nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review," Clinical Gastroenterology and Hepatology, vol. 10, no. 12, pp. 1342. e2-1359. e2, 2012.
8. A. Grieco, A. Forgione, L. Miele et al. , "Fatty liver and drugs," European Review forMedical and Pharmacological Sciences, vol. 9, no. 5, pp. 261-263, 2005.
9. G. Danan and C. Benichou, "Causality assessment of adverse reactions to drugs-I: a novel method based on the conclusions of international consensus meetings: application to druginduced liver injuries," Journal of Clinical Epidemiology, vol. 46, no. 11, pp. 1323-1330, 1993.
10. C. Benichou, G. Danan, and A. Flahault, "Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge," Journal of Clinical Epidemiology, vol. 46, no. 11, pp. 1331-1336, 1993.
11. C. A. Naranjo, U. Busto, and E. M. Sellers, "A method for estimating the probability of adverse drug reactions," Clinical Pharmacology and Therapeutics, vol. 30, no. 2, pp. 239-245, 1981.
12. V. A. J. Maria and R. M. M. Victorino, "Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis," Hepatology, vol. 26, no. 3, pp. 664-669, 1997.
13. N. Chalasani, Z. Younossi, J. E. Lavine et al. , "The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of LiverDiseases, AmericanCollege of Gastroenterology, and the American GastroenterologicalAssociation," Hepatology, vol. 55, no. 6, pp. 2005-2023, 2012.
14. C. A. Matteoni, Z. M. Younossi, T. Gramlich, N. Boparai, and A. J. McCullough, "Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity," Gastroenterology, vol. 116, no. 6, pp. 1413-1419, 1999.
15. E. M. Brunt, C. G. Janney, A. M. di Bisceglie, B. A. Neuschwander-Tetri, and B. R. Bacon, "Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions," The American Journal of Gastroenterology, vol. 94, no. 9, pp. 2467-2474, 1999.
16. D. E. Kleiner, E. M. Brunt, M. van Natta et al. , "Design and validation of a histological scoring systemfor nonalcoholic fatty liver disease," Hepatology, vol. 41, no. 6, pp. 1313-1321, 2005.
17. D. E. Kleiner, N. P. Chalasani, W. M. Lee et al. , "Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations," Hepatology, vol. 59, no. 2, pp. 661-670, 2014.
18. R. J. Andrade, M. I. Lucena, M. C. Fernandez et al. , "Druginduced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period," Gastroenterology, vol. 129, no. 2, pp. 512-521, 2005.
19. D. E. Kleiner, "The pathology of drug-induced liver injury," Seminars in Liver Disease, vol. 29, no. 4, pp. 364-372, 2009.
20. X. Zhang, J. Ouyang, and S. N. Thung, "Histopathologic manifestations of drug-induced hepatotoxicity," Clinics in Liver Disease, vol. 17, no. 4, pp. 547-564, 2013.
21. R. Ramachandran and S. Kakar, "Histological patterns in druginduced liver disease," Journal of Clinical Pathology, vol. 62, no. 6, pp. 481-492, 2009.
22. F. W. Guglielmi, D. Boggio-Bertinet, A. Federico et al. , "Total parenteral nutrition-related gastroenterological complications," Digestive and Liver Disease, vol. 38, no. 9, pp. 623-642, 2006.
23. S. Sahoo and J. Hart, "Hstopathological features of Lasparaginase-induced liver disease," Seminars in Liver Disease, vol. 23, no. 3, pp. 295-299, 2003.
24. E. Freneaux, G. Labbe, P. Letteron et al. , "Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: possible role in microvesicular steatosis induced by this antibiotic," Hepatology, vol. 8, no. 5, pp. 1056-1062, 1988.
25. S. Kimura, T. Kobayashi, Y. Tanaka, and Y. Sasaki, "Liver histopathology in clinical Reye syndrome," Brain and Development, vol. 13, no. 2, pp. 95-100, 1991.
26. P. Letteron, N. Brahimi-Bourouina, M.-A. Robin, A. Moreau, G. Feldmann, and D. Pessayre, "Glucocorticoids inhibit mitochondrial matrix acyl-CoA dehydrogenases and fatty acid β-oxidation," The American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 272, 1, no. 5, pp. G1141-G1150, 1997.
27. E. Freneaux, B. Fromently, A. Berson et al. , "Stereoselective and nonstereoselective effects of ibuprofen enantiomers on mitochondrial beta-oxidation of fatty acids," Journal of Pharmacology and Experimental Therapeutics, vol. 255, no. 2, pp. 529-535, 1990.
28. I. R. Wanless, S. Dore, N. Gopinath et al. , "Histopathology of cocaine hepatotoxicity. Report of four patients," Gastroenterology, vol. 98, no. 2, pp. 497-501, 1990.
29. F. Zhao, P. Xie, J. Jiang, L. Zhang, W. An, and Y. Zhan, "The effect and mechanism of tamoxifen-induced hepatocyte steatosis in vitro," International Journal of Molecular Sciences, vol. 15, no. 3, pp. 4019-4030, 2014.
30. J. D. Browning and J. D. Horton, "Molecular mediators of hepatic steatosis and liver injury," The Journal of Clinical Investigation, vol. 114, no. 2, pp. 147-152, 2004.
31. O. A. Gudbrandsen, T. H. Rost, and R. K. Berge, "Causes and prevention of tamoxifen-induced accumulation of triacylglycerol in rat liver," Journal of Lipid Research, vol. 47, no. 10, pp. 2223-2232, 2006.
32. A. P. Vitins, A. S. Kienhuis, E. N. Speksnijder, M. Roodbergen, M. Luijten, and L. T. M. van der Ven, "Mechanisms of amiodarone and valproic acid induced liver steatosis inmouse in vivo act as a template for other hepatotoxicity models," Archives of Toxicology, vol. 88, no. 8, pp. 1573-1588, 2014.
33. S. Antherieu, A. Rogue, B. Fromenty, A. Guillouzo, and M.-A. Robin, "Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in heparg cells," Hepatology, vol. 53, no. 6, pp. 1895-1905, 2011.
34. L. K. Cole, R. L. Jacobs, and D. E. Vance, "Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid synthesis," Hepatology, vol. 52, no. 4, pp. 1258-1265, 2010.
35. S. Zelber-Sagi, F. Salomone, H. Yeshua et al. , "Non-high-density lipoprotein cholesterol independently predicts new onset of non-alcoholic fatty liver disease," Liver International, vol. 34, no. 6, pp. e128-e135, 2014.
36. B. Fromenty, C. Fisch, G. Labbe et al. , "Amiodarone inhibits the mitochondrial β-oxidation and fatty acids and produces microvesicular steatosis of the liver in mice," Journal of Pharmacology and Experimental Therapeutics, vol. 255, no. 3, pp. 1371-1376, 1990.
37. I. Larosche, P. Letteron, B. Fromenty et al. , "Tamoxifen inhibits topoisomerases, depletes mitochondrial DNA, and triggers steatosis in mouse liver," Journal of Pharmacology and Experimental Therapeutics, vol. 321, no. 2, pp. 526-535, 2007.
38. A. Berson, V. de Beco, P. Letteron et al. , "Steatohepatitisinducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes," Gastroenterology, vol. 114, no. I, pp. 764-774, 1998.
39. S. Dalaklioglu, G. E. Genc, N. H. Aksoy, F. Akcit, and S. Gumuslu, "Resveratrol ameliorates methotrexate-induced hepatotoxicity in rats via inhibition of lipid peroxidation," Human and Experimental Toxicology, vol. 32, no. 6, pp. 662-671, 2013.
40. N. Jahovic, H. Çevik, A. O. Şehirli, B. Ç . Yeʇen, and G. Şener, "Melatonin prevents methotrexate-induced hepatorenal oxidative injury in rats," Journal of Pineal Research, vol. 34, no. 4, pp. 282-287, 2003.
41. S. Uraz, V. Tahan, C. Aygun et al. , "Role of ursodeoxycholic acid in prevention of methotrexate-induced liver toxicity," Digestive Diseases and Sciences, vol. 53, no. 4, pp. 1071-1077, 2008.
42. T. Çakir, E. Ózkan, E. Dulundu et al. , "Caffeic acid phenethyl ester (CAPE) prevents methotrexate-induced hepatorenal oxidative injury in rats," Journal of Pharmacy and Pharmacology, vol. 63, no. 12, pp. 1566-1571, 2011.
43. A. A. Albukhari, H. M. Gashlan, H. A. El-Beshbishy, A. A. Nagy, and A. B. Abdel-Naim, "Caffeic acid phenethyl ester protects against tamoxifen-induced hepatotoxicity in rats," Food and Chemical Toxicology, vol. 47, no. 7, pp. 1689-1695, 2009.
44. G. M. Suddek, "Protective role of thymoquinone against liver damage induced by tamoxifen in female rats," Canadian Journal of Physiology and Pharmacology, vol. 92, no. 8, pp. 640-644, 2014.
45. I. Jafarian, M. R. Eskandari, V. Mashayekhi, M. Ahadpour, and M.-J. Hosseini, "Toxicity of valproic acid in isolated rat livermitochondria," ToxicologyMechanisms and Methods, vol. 23, no. 8, pp. 617-623, 2013.
46. V. Tong, X. W. Teng, T. K. H. Chang, and F. S. Abbott, "Valproic acid II: effects on oxidative stress, mitochondrial membrane potential, and cytotoxicity in glutathione-depleted rat hepatocytes," Toxicological Sciences, vol. 86, no. 2, pp. 436-443, 2005.
47. F. Salomone, G. Li Volti, C. Rosso, G. Grosso, and E. Bugianesi, "Unconjugated bilirubin, a potent endogenous antioxidant, is decreased in patients with non-alcoholic steatohepatitis and advanced fibrosis," Journal of Gastroenterology and Hepatology, vol. 28, no. 7, pp. 1202-1208, 2013.
48. M. K. Tawfik, "Combination of coenzyme Q10 with methotrexate suppresses Freunds complete adjuvant-induced synovial inflammation with reduced hepatotoxicity in rats: effect on oxidative stress and inflammation," International Immunopharmacology, vol. 24, no. 1, pp. 80-87, 2015.
49. S. Mukherjee, S. Ghosh, S. Choudhury et al. , "Pomegranate reverses methotrexate-induced oxidative stress and apoptosis in hepatocytes by modulating Nrf2-NF-κB pathways," Journal of Nutritional Biochemistry, vol. 24, no. 12, pp. 2040-2050, 2013.
50. N. Ali, S. Rashid, S. Nafees, S. K. Hasan, and S. Sultana, "Beneficial effects of Chrysin against Methotrexate-induced hepatotoxicity via attenuation of oxidative stress and apoptosis," Molecular and Cellular Biochemistry, vol. 385, no. 1-2, pp. 215-223, 2014.
51. I. S. Elefsiniotis, K. D. Pantazis, A. Ilias et al. , "Tamoxifen induced hepatotoxicity in breast cancer patients with preexisting liver steatosis: the role of glucose intolerance," European Journal of Gastroenterology and Hepatology, vol. 16, no. 6, pp. 593-598, 2004.
52. V. Biton, W. Mirza, G. Montouris, A. Vuong, A. E. Hammer, and P. S. Barrett, "Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy," Neurology, vol. 56, no. 2, pp. 172-177, 2001.
53. J. I. T. Isojärvi, J. Rättyä, V. V. Myllylä et al. , "Valproate, lamotrigine, and insulin-mediated risks inwomen with epilepsy," Annals of Neurology, vol. 43, no. 4, pp. 446-451, 1998.
54. Y. Yilmaz, "Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?" Alimentary Pharmacology and Therapeutics, vol. 36, no. 9, pp. 815-823, 2012.
55. H. Tilg and A. R. Moschen, "Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis," Hepatology, vol. 52, no. 5, pp. 1836-1846, 2010.
56. G. N. Ioannou, W. G. Haigh, D. Thorning, and C. Savard, "Hepatic cholesterol crystals and crown-like structures distinguish NASH fromsimple steatosis," The Journal of Lipid Research, vol. 54, no. 5, pp. 1326-1334, 2013.
57. S. Bruno, P. Maisonneuve, P. Castellana et al. , "Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial," British Medical Journal, vol. 330, no. 7497, pp. 932-935, 2005.
58. R. N. Hardwick, C. D. Fisher, S. M. Street, M. J. Canet, and N. J. Cherrington, "Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis," Drug Metabolism and Disposition, vol. 40, no. 3, pp. 450-460, 2012.
59. R. N. Hardwick, J. D. Clarke, A. D. Lake et al. , "Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis," Toxicological Sciences, vol. 142, no. 1, pp. 45-55, 2014.
60. A. D. Lake, P. Novak, C. D. Fisher et al. , "Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease," Drug Metabolism and Disposition, vol. 39, no. 10, pp. 1954-1960, 2011.
61. P. Vassallo and R. G. Trohman, "Prescribing amiodarone: an evidence-based review of clinical indications," The Journal of the AmericanMedical Association, vol. 298, no. 11, pp. 1312-1322, 2007.
62. A. E. Rätz Bravo, J. Drewe, R. G. Schlienger, S. Krähenbühl, H. Pargger, and W. Ummenhofer, "Hepatotoxicity during rapid intravenous loading with amiodarone: description of three cases and review of the literature," Critical Care Medicine, vol. 33, no. 1, pp. 128-134, 2005.
63. F. Giannattasio, A. Salvio, M. Varriale, F. P. Picciotto, G. G. di Costanzo, and M. Visconti, "Three cases of severe acute hepatitis after parenteral administration of amiodarone: the active ingredient is not the only agent responsible for hepatotoxicity," Annali Italiani di Medicina Interna, vol. 17, no. 3, pp. 180-184, 2002.
64. A. Rhodes, J. B. Eastwood, and S. A. Smith, "Early acute hepatitis with parenteral amiodarone: a toxic effect of the vehicle?" Gut, vol. 34, no. 4, pp. 565-566, 1993.
65. P. R. James and S. M. C. Hardman, "Acute hepatitis complicating parenteral amiodarone does not preclude subsequent oral therapy," Heart, vol. 77, no. 6, pp. 583-584, 1997.
66. J. S. Kicker, J. A. Haizlip, and M. L. Buck, "Hepatotoxicity after continuous amiodarone infusion in a postoperative cardiac infant," The Journal of Pediatric Pharmacology and Therapeutics, vol. 17, no. 2, pp. 189-195, 2012.
67. M. Nasser, T. R. Larsen, B. Waanbah, I. Sidiqi, and P. A. McCullough, "Hyperacute drug-induced hepatitis with intravenous amiodarone: case report and review of the literature," Drug, Healthcare and Patient Safety, vol. 5, no. 1, pp. 191-198, 2013.
68. J. J. Heger, E. N. Prystowsky, W. M. Jackman et al. , "Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation," The New England Journal of Medicine, vol. 305, no. 10, pp. 539-545, 1981.
69. J. H. Lewis, R. C. Ranard, A. Caruso et al. , "Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients," Hepatology, vol. 9, no. 5, pp. 679-685, 1989.
70. W. Mattar, B. Juliar, I. Gradus-Pizlo, and P. Y. Kwo, "Amiodarone hepatotoxicity in the context of the metabolic syndrome and right-sided heart failure," Journal of Gastrointestinal and Liver Diseases, vol. 18, no. 4, pp. 419-423, 2009.
71. L. Llanos, R. Moreu, A. M. Peiŕo et al. , "Causality assessment of liver injury after chronic oral amiodarone intake," Pharmacoepidemiology and Drug Safety, vol. 18, no. 4, pp. 291-300, 2009.
72. K. Raja, S. N. Thung, M. I. Fiel, and C. Chang, "Druginduced steatohepatitis leading to cirrhosis: long-term toxicity of amiodarone use," Seminars in Liver Disease, vol. 29, no. 4, pp. 423-428, 2009.
73. N. Goldschlager, A. E. Epstein, G. V. Naccarelli et al. , "Apractical guide for clinicians who treat patients with amiodarone: 2007," Heart Rhythm, vol. 4, no. 9, pp. 1250-1259, 2007.
74. L. C. C. Kum, W. W. L. Chan, H. H. Y. Hui et al. , "Prevalence of amiodarone-related hepatotoxicity in 720 Chinese patientswith or without baseline liver dysfunction," Clinical Cardiology, vol. 29, no. 7, pp. 295-299, 2006.
75. J. H. Lewis, F. Mullick, K. G. Ishak et al. , "Histopathologic analysis of suspected amiodarone hepatotoxicity," Human Pathology, vol. 21, no. 1, pp. 59-57, 1990.
76. S. R. Puli, M. A. Fraley, V. Puli, A. B. Kuperman, and M. A. Alpert, "Hepatic cirrhosis caused by low-dose oral amiodarone therapy,"The American Journal of theMedical Sciences, vol. 330, no. 5, pp. 257-261, 2005.
77. C.-C. Chang, M. Petrelli, J. F. Tomashefski Jr. , and A. J. McCullough, "Severe intrahepatic cholestasis caused by amiodarone toxicity after withdrawal of the drug: a case report and review of the literature,"Archives of Pathology and LaboratoryMedicine, vol. 123, no. 3, pp. 251-256, 1999.
78. D. B. Jones, F. G. Mullick, J. H. Hoofnagle, and B. Baranski, "Reyes syndrome-like illness in a patient receiving amiodarone," The American Journal of Gastroenterology, vol. 83, no. 9, pp. 967-969, 1988.
79. B. Rigas, L. E. Rosenfeld, K. W. Barwick et al. , "Amiodarone hepatotoxicity. A clinicopathologic study of five patients," Annals of Internal Medicine, vol. 104, no. 3, pp. 348-351, 1986.
80. G. C. Farrell, "Drugs and steatohepatitis," Seminars in Liver Disease, vol. 22, no. 2, pp. 185-194, 2002.
81. J. F. Brien, S. Jimmo, F. J. Brennan, S. E. Ford, and P. W. Armstrong, "Distribution of amiodarone and its metabolite, desethylamiodarone, in human tissues," Canadian Journal of Physiology and Pharmacology, vol. 65, no. 3, pp. 360-364, 1987.
82. J. Markos, M. E. Veronese, M. R. Nicholson, S. McLean, and J. E. Shevland , "Value of hepatic computerized tomographic scanning during amiodarone therapy," The American Journal of Cardiology, vol. 56, no. 1, pp. 89-92, 1985.
83. P. Kaufmann, M. Török, A. Hänni, P. Roberts, R. Gasser, and S. Krähenbühl, "Mechanisms of benzarone and benzbromaroneinduced hepatic toxicity," Hepatology, vol. 41, no. 4, pp. 925-935, 2005.
84. O. O. Oyetayo, C. E. Rogers, and P. O. Hofmann, "Dronedarone: a new antiarrhythmic agent," Pharmacotherapy, vol. 30, no. 9, pp. 904-915, 2010.
85. S. H. Hohnloser, H. J. G. M. Crijns, M. van Eickels et al. , "Effect of dronedarone on cardiovascular events in atrial fibrillation," The New England Journal of Medicine, vol. 360, no. 7, pp. 668-678, 2009.
86. B. N. Singh, S. J. Connolly, H. J. G. M. Crijns et al. , "Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter," The New England Journal of Medicine, vol. 357, no. 10, pp. 987-999, 2007.
87. "In brief: FDA warning on dronedarone (Multaq)," TheMedical Letter on Drugs and Therapeutics, vol. 53, no. 1359, p. 17, 2011.
88. A. Felser, K. Blum, P. W. Lindinger, J. Bouitbir, and S. Krähenbühl, "Mechanisms of hepatocellular toxicity associated with dronedarone-a comparison to amiodarone," Toxicological Sciences, vol. 131, no. 2, pp. 480-490, 2013.
89. A. Felser, A. Stoller, R. Morand et al. , "Hepatic toxicity of dronedarone in mice: Role of mitochondrial β-oxidation," Toxicology, vol. 323, pp. 1-9, 2014.
90. C. Perez, W. W. Sutow, Y. M. Wang, and J. Herson, "Evaluation of overall toxicity of high-dosage methotrexate regimens," Medical and Pediatric Oncology, vol. 6, no. 3, pp. 219-228, 1979.
91. R. K. Bath, N. K. Brar, F. A. Forouhar, and G. Y. Wu, "A review of methotrexate-associated hepatotoxicity," Journal of Digestive Diseases, vol. 15, no. 10, pp. 517-524, 2014.
92. G. Schmajuk, Y. Miao, J. Yazdany, W. J. Boscardin, D. I. Daikh, and M. A. Steinman, "Identification of risk factors for elevated transaminases in methotrexate users through an electronic health record," Arthritis Careand Research, vol. 66, no. 8, pp. 1159-1166, 2014.
93. M. R. Fournier, J. Klein, G. Y. Minuk, and C. N. Bernstein, "Changes in liver biochemistry during methotrexate use for inflammatory bowel disease," The American Journal of Gastroenterology, vol. 105, no. 7, pp. 1620-1626, 2010.
94. A. Goyal, J. S. Hyams, T. Lerer et al. , "Liver enzyme elevations within threemonths of diagnosis of inflammatory bowel disease and likelihood of liver disease," Journal of Pediatric Gastroenterology and Nutrition, vol. 20, no. 8, pp. 1341-1345, 2014.
95. P. L. Valentino, P. C. Church, P. S. Shah et al. , "Hepatotoxicity caused by methotrexate therapy in children with inflammatory bowel disease: a systematic review and meta-analysis," Inflammatory Bowel Diseases, vol. 20, no. 1, pp. 47-59, 2014.
96. R. Sotoudehmanesh, B. Anvari, M. Akhlaghi, S. Shahraeeni, and S. Kolahdoozan, "Methotrexate hepatotoxicity in patients with rheumatoid arthritis,"Middle East Journal of Digestive Diseases, vol. 2, no. 2, pp. 104-109, 2010.
97. M. A. M. Berends, J. Snoek, E. M. G. J. de Jong et al. , "Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent," Alimentary Pharmacology and Therapeutics, vol. 24, no. 5, pp. 805-811, 2006.
98. Q. E. Whiting-OKeefe, K. H. Fye, and K. D. Sack, "Methotrexate and histologic hepatic abnormalities: a meta-analysis," The American Journal of Medicine, vol. 90, no. 6, pp. 711-716, 1991.
99. M. F. Dawwas and G. P. Aithal, "End-stage methotrexate-related liver disease is rare and associatedwith features of themetabolic syndrome," Alimentary Pharmacology and Therapeutics, vol. 40, no. 8, pp. 938-948, 2014.
100. S. Kevat, M. Ahern, and P. Hall, "Hepatotoxicityofmethotrexate in rheumatic diseases," Medical Toxicology and Adverse Drug Experience, vol. 3, no. 3, pp. 197-208, 1988.
101. M.-H. Lee, I. Hong, M. Kim et al. , "Gene expression profiles of murine fatty liver induced by the administration of methotrexate," Toxicology, vol. 249, no. 1, pp. 75-84, 2008.
102. T. Saphner, S. Triest-Robertson, H. Li, and P. Holzman, "The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer," Cancer, vol. 115, no. 14, pp. 3189-3195, 2009.
103. Y. Murata, Y. Ogawa, T. Saibara et al. , "Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients," Oncology Reports, vol. 7, no. 6, pp. 1299-1304, 2000.
104. T. Ohnishi, Y. Ogawa, T. Saibara et al. , "CYP17 polymorphism and tamoxifen-induced hepatic steatosis," Hepatology Research, vol. 33, no. 2, pp. 178-180, 2005.
105. P. R. Powell-Jackson, J. M. Tredger, and R. Williams, "Hepatotoxicity to sodium valproate: a review," Gut, vol. 25, no. 6, pp. 673-681, 1984.
106. F. E. Dreifuss, N. Santilli, D. H. Langer, K. P. Sweeney, K. A. Moline, and K. B. Menander, "Valproic acid hepatic fatalities: a retrospective review," Neurology, vol. 37, no. 3, pp. 379-385, 1987.
107. D. Scheffner, I. Rauterberg-Ruland , W. Kochen, and W. J. Hofmann, "Fatal liver failure in 16 children with valproate therapy," Epilepsia, vol. 29, no. 5, pp. 530-542, 1988.
108. M. M. Schmid, R. W. Freudenmann, F. Keller et al. , "Nonfatal and fatal liver failure associated with valproic acid," Pharmacopsychiatry, vol. 46, no. 2, pp. 63-68, 2013.
109. M. F. B. Silva, C. C. P. Aires, P. B. M. Luis et al. , "Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review," Journal of Inherited Metabolic Disease, vol. 31, no. 2, pp. 205-216, 2008.
110. H. J. Zimmerman and K. G. Ishak, "Valproate induced hepatic injury: analyses of 23 fatal cases," Hepatology, vol. 2, no. 5, pp. 591-597, 1982.
111. V. Belcastro, C. DEgidio, P. Striano, and A. Verrotti, "Metabolic and endocrine effects of valproic acid chronic treatment," Epilepsy Research, vol. 107, no. 1-2, pp. 1-8, 2013.
112. G. J. Luef, M. Waldmann, W. Sturm et al. , "Valproate therapy and nonalcoholic fatty liver disease," Annals of Neurology, vol. 55, no. 5, pp. 729-732, 2004.
113. L.-F. Zhang, L.-S. Liu, X.-M. Chu et al. , "Combined effects of a high-fat diet and chronic valproic acid treatment on hepatic steatosis and hepatotoxicity in rats," Acta Pharmacologica Sinica, vol. 35, no. 3, pp. 363-372, 2014.
114. M. F. B. Silva, J. P. N. Ruiter, L. IJlst et al. , "Synthesis and intramitochondrial levels of valproyl-coenzyme Ametabolites," Analytical Biochemistry, vol. 290, no. 1, pp. 60-67, 2001.
115. C. C. P. Aires, L. IJlst, F. Stet et al. , "Inhibition of hepatic carnitine palmitoyl-transferase I (CPT IA) by valproyl-CoA as a possiblemechanism of valproate-induced steatosis," Biochemical Pharmacology, vol. 79, no. 5, pp. 792-799, 2010.
116. I. Mannaerts, N. R. Nuytten, V. Rogiers, K. Vanderkerken, L. A. Van Grunsven, and A. Geerts, "Chronic administration of valproic acid inhibits activation ofmouse hepatic stellate cells in vitro and in vivo," Hepatology, vol. 51, no. 2, pp. 603-614, 2010.
117. M. S. Sulkowski, D. L. Thomas, R. E. Chaisson, and R. D. Moore, "Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection,"The Journal of the American Medical Association, vol. 283, no. 1, pp. 74-80, 2000.
118. J. C. Price and C. L. Thio, "Liver disease in the HIV-infected individual," Clinical Gastroenterology and Hepatology, vol. 8, no. 12, pp. 1002-1012, 2010.
119. K. Gardner, P. A. Hall, P. F. Chinnery, and B. A. I. Payne, "HIV treatment and associated mitochondrial pathology: review of 25 years of in vitro, animal, and human studies," Toxicologic Pathology, vol. 42, no. 5, pp. 811-822, 2013.
120. N. Crum-Cianflone, A. Dilay, G. Collins et al. , "Nonalcoholic fatty liver disease among HIV-infected persons," Journal of Acquired Immune Deficiency Syndromes, vol. 50, no. 5, pp. 464-473, 2009.
121. G. Guaraldi, N. Squillace, C. Stentarelli et al. , "Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors," Clinical Infectious Diseases, vol. 47, no. 2, pp. 250-257, 2008.
122. S. Grinspoon and A. Carr, "Cardiovascular risk and body-fat abnormalities inHIV-infected adults,"TheNew England Journal of Medicine, vol. 352, no. 1, pp. 48-62, 2005.
123. K. Sundar, M. Suarez, P. E. Banogon, and J. M. Shapiro, "Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patients and reviewof the literature," Critical CareMedicine, vol. 25, no. 8, pp. 1425-1430, 1997.
124. M. A. Akhtar, K. Mathieson, B. Arey et al. , "Hepatic histopathology and clinical characteristics associated with antiretroviral therapy in HIV patients without viral hepatitis," European Journal of Gastroenterology and Hepatology, vol. 20, no. 12, pp. 1194-1204, 2008.
125. J.-P. Duong van Huyen, A. Landau, C. Piketty et al. , "Toxic effects of nucleoside reverse transcriptase inhibitors on the liver: value of electron microscopy analysis for the diagnosis of mitochondrial cytopathy," The American Journal of Clinical Pathology, vol. 119, no. 4, pp. 546-555, 2003.
126. J.-P. D. van Huyen, D. Batisse, D. Heudes et al. , "Alteration of cytochrome oxidase subunit I labeling is associated with severe mitochondriopathy in NRTI-related hepatotoxicity in HIV patients," Modern Pathology, vol. 19, no. 10, pp. 1277-1288, 2006.
127. M. V. Stankov, D. Panayotova-Dimitrova, M. Leverkus et al. , "Autophagy inhibition due to thymidine analogues as novel mechanism leading to hepatocyte dysfunction and lipid accumulation," AIDS, vol. 26, no. 16, pp. 1995-2006, 2012.
128. A. Igoudjil, J. Massart, K. Begriche, V. Descatoire, M.-A. Robin, and B. Fromenty, "High concentrations of stavudine impair fatty acid oxidation without depleting mitochondrial DNA in cultured rat hepatocytes," Toxicology in Vitro, vol. 22, no. 4, pp. 887-898, 2008.
129. A. B. Benson III, A. P. Venook, T. Bekaii-Saab et al. , "Colon cancer, version 3. 2014," Journal of the National Comprehensive Cancer Network, vol. 12, no. 7, pp. 1028-1059, 2014.
130. J.-N. Vauthey, T. M. Pawlik, D. Ribero et al. , "Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases," Journal of Clinical Oncology, vol. 24, no. 13, pp. 2065-2072, 2006.
131. C. G. Moertel, T. R. Fleming, J. S. Macdonald, D. G. Haller, and J. A. Laurie, "Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy," Journal of Clinical Oncology, vol. 11, no. 12, pp. 2386-2390, 1993.
132. P. D. Peppercorn, R. H. Reznek, P. Wilson, M. L. Slevin, and R. K. Gupta, "Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer," British Journal of Cancer, vol. 77, no. 11, pp. 2008-2011, 1998.
133. K. Miyake, K. Hayakawa, M. Nishino, T. Morimoto, and S. Mukaihara, "Effects of oral 5-fluorouracil drugs on hepatic fat content in patients with colon cancer," Academic Radiology, vol. 12, no. 6, pp. 722-727, 2005.
134. C. H. C. Pilgrim, K. Brettingham-Moore, A. Pham et al. , "mRNA gene expression correlates with histologically diagnosed chemotherapy-induced hepatic injury," HPB, vol. 13, no. 11, pp. 811-816, 2011.
135. D. McWhirter, N. Kitteringham, R. P. Jones, H. Malik, K. Park, and D. Palmer, "Chemotherapy induced hepatotoxicity in metastatic colorectal cancer: a review of mechanisms and outcomes," Critical Reviews in Oncology/Hematology, vol. 88, no. 2, pp. 404-415, 2013.
136. H. Zhang, J. M. Barceĺo, B. Lee et al. , "Human mitochondrial topoisomerase I," Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 19, pp. 10608-10613, 2001.
137. M. Bower, C. Wunderlich, R. Brown, C. R. Scoggins, K. M. McMasters, and R. C. G. Martin, "Obesity rather than neoadjuvant chemotherapy predicts steatohepatitis in patients with colorectal metastasis," American Journal of Surgery, vol. 205, no. 6, pp. 685-690, 2013.
138. E. Parkin, D. A. OReilly, R. Adam et al. , "The effect of hepatic steatosis on survival following resection of colorectal liver metastases in patients without preoperative chemotherapy," HPB, vol. 15, no. 6, pp. 463-472, 2013.
139. E. Parkin, D. A. OReilly, R. Adam et al. , "Equivalent survival in patients with and without steatosis undergoing resection for colorectal liver metastases following pre-operative chemotherapy," European Journal of Surgical Oncology, vol. 40, no. 11, pp. 1436-1444, 2014.
140. C. Reissfelder, K. Brand , J. Sobiegalla et al. , "Chemotherapyassociated liver injury and its influence on outcome after resection of colorectal liver metastases," Surgery, vol. 155, no. 2, pp. 245-254, 2014.